Good afternoon, and thank you for joining us this week at the J.P. Morgan Healthcare Conference. I'm Andrew Liang with J.P. Morgan, and with me today to present from the company is Raymond Cohen, CEO of Axonics. Dan Dearen, Chief Financial Officer, will also be joining for Q&A. Ray, I'll turn it over to you. Thank you. Good evening. I'm cognizant of the fact that it's now 4:30, and the only thing standing between you and a cocktail would be my presentation, so we'll try to be brief. Thanks for attending. Axonics is clearly focused on being able to treat women primarily who have some form of incontinence, whether that's fecal incontinence, whether it's urge urinary incontinence, where people can't get to the bathroom in time, or stress urinary incontinence, which affects a lot of women following childbirth, where they cough, sneeze or pick up an object or exercise and leak a little bit of urine. That's our business. That's what we're focused on. We've been public since October, since Halloween night in 2018. It's been four years being a public company, three years in the marketplace in the United States. In terms of our philosophy as of a company, we stick clearly to the notion that we're real clear about what our purpose is. All of our employees are clear about that. We value thoughtful innovation, which means that, you know, we do things very purposeful and for a reason, and integrity and quality is critical to the success of our company. Today, here with me, I've got a couple of our colleagues who traveled up to JPM from Southern California. I've got a very experienced management team. In addition to my colleague, Dan Dearen, who we'll hear from a little bit later. Rinda Sama, who's our Chief Operating Officer, is here with us in the audience as well. We're very fortunate to have Karen Noblett as the Chief Medical Officer. Dr. Noblett is one of the world's experts on the treatment of overactive bladder and stress urinary incontinence, and she's been with us a number of years from prior the IPO. We have a ringer, Dr. John Woock, who actually has a PhD in neuromodulation for control of the bladder. We got a bonafide expert on our team, and then a Chief Commercial Officer, Al Ford, and you can see, you know, how well we've done in terms of putting numbers on the board. Great leader of men and women. We got a good team, an experienced team. Most of these individuals I've worked with in some cases for over two decades in multiple different projects during this period of time. Our main business is sacral neuromodulation. And what is it that sacral neuromodulation treats? It's overactive bladder, fundamentally, also bowel dysfunction, which sometimes referred to as fecal incontinence or some form of it. In terms of, you know, what it is, OAB is that you just can't get to the bathroom in time. You have urgency, but you can't get to the bathroom in time, and you leak urine. This is a condition that some patients or some people might have this occurrence five, six, seven, 10 times in a day. You can imagine that takes over your life. You can't live a normal life when you constantly have to think about where's the bathroom, how do I get to the bathroom? Oh, my God, I'm gonna have an accident. It really does impact the quality of people's lives. Now, with sacral neuromodulation, we not only treat what's called urgency incontinence, which I just described, but we also treat the frequency that comes along with this. Great frequency, we can tamp that down with neuromodulation as well. Oddly enough, we actually treat the opposite of the problem, which is where people can't void or they have incomplete voiding of their bladder. The therapy, implanted in the exact same spot, programmed in the exact same way, treats all of those problems at the same time, in addition to fecal incontinence. As it turns out, about a third of the people who suffer from overactive bladder also have some form of fecal incontinence. Sometimes that, you know, will occur at the same time they have the bladder accident, they'll have a bowel accident to go along with it. You can see this is difficult. A lot of people are affected by this problem. I mean, these are tens of millions of adults that are afflicted with either overactive bladder or fecal incontinence. All in, it's nearly 60 million people that are suffering from the problems, and these are, you know, these are U.S. numbers that we're quoting. Unfortunately, only about half of them seek treatment because there's a lot of wives' tales out there that somehow this is part of normal part of aging and so on and so forth, and just your lot in life. The reality is that, you know, we have treatments now, and the good news is this product of sacral neuromodulation that we market is nicely reimbursed. You know, in the United States, you know, physicians get paid well for doing the implants and the institutions where they do them, whether they be in an outpatient section of a hospital or in an ambulatory surgery center, they're able to receive reimbursement. Axonics did not invent sacral neuromodulation, but we perfected it. Okay? It's been commercially available for a long time, and Medtronic was the only player in the marketplace before Axonics came around and started to ship our first commercial products in the United States in November of 2019. How does it work? Basically, there's a lead that's implanted, and it's tunneled down through your sacrum, and it sits next to your sacral nerve, and then that lead is attached to a small neurostimulator, which is implanted in the upper buttocks of the patient's body. Simple as that. It's not a big surgery. Takes maybe in good hands, somewhere in the neighborhood of 15 to 30 minutes to be able to do the procedure. The way it works is that we send electrical signals from the bladder and the bowel to the brain, and it normalizes those signals and basically tamps down, you know, this urgency issue and these accidents that typically would have occurred. It's been around for a while, so there's no question about whether this works. We saw in our own clinical studies efficacy in around the 90% range. People are getting real relief from the therapy that we provide. We entered a market that had a product that really wasn't that great. The product only lasted two to five years in the body. It wasn't MRI compatible, meaning that if the patient needed to get an MRI, they had to go and get the device explanted from the body, thrown in the garbage, and if they wanted to continue to have symptom relief, to get reimplanted. That's the market that we, you know, how should we say, entered, right? The device was kind of large, and it was fairly complicated to use. That's kinda what, you know, the state of the market was when we entered back in November 2019. We spend a lot of time talking about the total addressable market or the size of this opportunity, and it is quite substantial, as you can see from these slides. If you take all of the procedures for sacral neuromodulation, we're talking 2022 numbers, right? You take Medtronic and Axonics, you add it together. That equals 50,000 total implants. You then add 150,000 BOTOX on top of that number. You throw in a little bit of the PTNS, where people put a needle into the tibial nerve. They sit in a chair, so to speak, and get these treatments over, you know, a couple hours, over a couple of months. Not that it doesn't work that well. Nevertheless, we've got a bunch of these folks when you add it together. You add it all together, we call them third-line therapies. That's 220,000 people. The total uptake of third-line therapies as compared to the people who've been differentially diagnosed with this problem means that we only got about a 3% market penetration. If you look at what is it that we're doing, right, in terms of sacral neuromodulation, you can see that it's less than, you know, it's 0.2%. This is a huge opportunity, a big green field ahead of us. The key thing is to be able to educate more patients, make them aware that it's not normal to live with this condition, and there's therapies out there that can help you. We got a long way to go, and we feel like we're scratching the surface. The fact that Medtronic was out there for 20 years, they just didn't focus on it. They didn't do any education and create awareness in the marketplace. There, you know, therein lies kind of the problem. We see now this market is expanding. When we entered, the market in the United States was about $500 billion. It's up to about $800 million now. We believe that the market is growing at a 15% annual compounded annual growth rate. We think this market's gonna be $1.5 billion in the next three to five years. That's what's happening. Why is the market now accelerating? We're now offering products to patients that can last 20 years in your body. The average patient that we're treating is a 57-year-old woman. You know, this is basically a product now that can last for the rest of their life, so it's much more attractive. The devices are small. In terms of the size of the device that gets implanted, we have a rechargeable device that's five cc's. That's the size of an Andes Mint, if you've ever seen those little green mints, right? Really small little device. It's not a big pacemaker that somebody's gonna have in their upper buttocks. Our non-rechargeable device is 10 cc's, also very small, very thin, and so on and so forth. These devices are long-lived in the body. That's the key. That's what people want. They want a long life, and they want efficacy. Those are the key elements. Anyway, in the past, it's been a bit of a secret therapy, you know, offered by a company that this wasn't a big deal. For Axonics, this is, this is our business, and we're 100% focused on it. We're gonna create more awareness. We're gonna continue to do the things that we need to do. Here's an example, just a quick comparison between the product that you see on the right of your screen, which is the Axonics rechargeable device. That's the first product that we put in the marketplace. You know, you can see that it's much smaller. You know, that quarter was put there very much on purpose. You can see it's not a big deal in terms of what it is. You know, we brought a new technology to market that makes the product work more efficiently. We introduced in the Q2 of this year, our first recharge-free system, which can last up to 22 years in the body, doesn't need to be recharged, and uses a patient remote that you can hold in front of yourself like I'm holding this clicker, and it can communicate with the device and so on and so forth. Very, very easy. Very simple. This has been a huge winner for us. It now accounts for two-thirds of our business. Here's an example of comparing our product against our competitive product. You can see that along the top is a designation of amplitude. This gives you an indication of the quality of the implant that you're doing. Obviously, the less, the lower amount of energy that you need to create neural activation to create symptom relief is going to have the device last longer in the body, right? We see that with our implanters that can easily get anything less than one or below one milliamp. A half a milliamp happens on a regular basis every day, anywhere from 17.5-25 years. This is incredible in terms of where you were three years ago, where if you wanted this therapy, it was two to five years in the body. We've come a long way in a short period of time. In terms of results, we have 93% of the patients that are treated with our device are therapy responders, and 82% of them are better than 75% improved, right? We got a bunch of them. Almost 40% of them are completely dry. They, in fact, are gonna be cured as long as the device is working in their body. Even for the people that are not dry, they're significantly improved. It's not like we just, you know, got over the line. You know, we're providing people serious symptom relief that matters. In our clinical study, the average patient was leaking nearly six times a day, and then we're down to, you know, one or less. Now, in addition to Sacral Neuromodulation, we acquired a product which is called Bulkamid. This is a product for patients who have stress urinary incontinence. It's the other side of the coin. This is where you cough, you sneeze, you pick up an object, you exercise, you leak a little bit of urine. Nearly, but I think it's 28 million women in the United States have this particular problem, primarily caused by a weakening of the pelvic floor and the fact that their urethra has, how should we say, is larger than it was naturally. Okay? That's what the issue is, and then we have a hydrogel that's injected into the urethra, we create these cushions, we kind of bulk it up, and that solves the problem for these folks. It's a device. It comes with a scope that's specifically designed for the female anatomy and with a hydrogel that's easy to use. It doesn't degrade. It's biocompatible. It's easy to say yes to this because it's something can be done, you know, in a 15-minute procedure. Patient does a cough test, they're dry, and life is really good, and it's gonna last five or seven years. Simple as that. This product has been a big winner for us, but if you talk about, you know, what's going on out there, same story. Right? We in 2022, we have really changed the game in terms of women saying yes to Bulkamid as opposed to doing a sling operation, which is a complicated surgery with lots of downtime and so on and so forth. You know, cutting to the chase, once again, out of the people who've been differentially diagnosed with this problem, over five million patients and maybe 150,000 people have gotten treated. The penetration in both, in this general market segment is extremely low compared to, you know, what the potential is. We have a large commercial footprint in the United States. We have about 355 people between representatives carrying quotas and clinical specialists. We have some people in Europe as well, and, you know, we're well-staffed, and we believe that, you know, we can double our revenue with the same commercial footprint, so we don't need to be adding a whole bunch of other folks to the mix. It's a combination of folks specifically focused on selling Sacral Neuromodulation, those specifically focused on selling Bulkamid, the cross-selling that goes on, and then clinical specialists. These are all nurses. These are either nurse practitioners, physician assistants or RNs and they're in there, you know, making sure the procedures go well and patients are programmed well and so on and so forth. That's our team. We got full coverage all over the United States and so on and so forth. In 2022, we started a direct-to-consumer campaign. We're on Facebook. We're also on national television with a commercial that's very straightforward, a 30-second commercial which basically says, "Hey, it's not normal to leak urine." Okay? Axonics has therapies that can help you. Let us get you with a provider, you know, to get you relief. Simple as that. Basically, we call those individuals, and our goal is to get them placed into a physician's office for a consult so they can get worked up and ultimately get the therapy that they need. If I go back, talk a little bit about our financial results. We're obviously very proud of what we've been able to accomplish in a short period of time. We introduced the product in November 2019, so we had two months of revenue in the United States. We put $14 million on the board, then we entered, you know, the 2020 period, some people may remember that around February 2020, kind of the world ended with COVID. That was a tough period of time for us, but nevertheless, we managed to sell $112 million worth of sacral neuromodulation in 2020, $180 million in 2021, and we just finished 2024 at $274 million, which represents, you know, 52% growth year-over-year. We're proud of what we've been able to accomplish to date. We put out guidance today, and we believe that we can do, you know, over $340 million in 2023. Another nice thing that's happened during this period of time is that we were named the number one fastest growing company in the Americas last year, or I should say in 2021. In 2022, we were the fourth fastest growing company. We're proud of what we accomplished, but we feel like we're just getting started. We've got these huge markets that we can sell into. They're under-penetrated. People just really don't know about these therapies. That's why we think between increasing our customer base, doing DTC, the combination of all those aspects are all gonna conspire to allow us to continue. I would say that we're also in a great financial position in the sense that we have $350 million of cash on our balance sheet. We have no debt, and we're also now we have positive adjusted EBITDA as well. You know, we're it's not just about spending money and growing the revenue. We're looking to be profitable. The first step, of course, is to be cash flow positive and have adjusted EBITDA as well. That's the story in a nutshell in 19 minutes. We're happy to take some questions from the audience. Great. Thank you very much. At this time, we'll open up to Q&A from the floor, but perhaps maybe just to kick us off, you know, you guys have consistently said that you expect the S&M market to double over a five-year period, and this translate to, you know, a $1.5 billion market over the next several years and market expansion of 15% annually. What gives you confidence in this outlook? If you just look at the prevalence and incidents and how many prospective patients have this condition. In the U.S. alone, you have 78 million women that suffer from moderate to severe incontinence, and you can take it down two paths. One path is you've got approximately 40 million that are suffering from overactive bladder, and some large percentage of that have idiopathic overactive bladder, which is ideally suited for the sacral neuromodulation product line. You have, as Ray mentioned, 28 million-30 million women that have stress urinary incontinence, which brings them down the path of Bulkamid. For the first time ever in the past 25 years, Axonics has brought innovation to this market. We have a very large commercial footprint, and we're marketing, and we're in these practices taking care of the patients and making sure that the patients are getting the therapy they deserve and seeing great results. Because of these innovations and this attention to detail on customer service, for the first time you're seeing physicians have confidence in these products. They're talking to these patients, and then these patients are saying yes. Over the past few years, what we've seen are new physicians wanting to get into this practice and existing physicians who were not as sold on the benefits of the therapy coming back online, asking to be retrained using our products and doing more procedures. We're seeing an increase in utilization or same-store sales. It's just hard to imagine with 78 million women in the U.S., this market's not going to grow at least 15% per year for the next five years, which is why our vision has been this will be a $1.5 billion-$2 billion market carved up in some form or fashion between Axonics and Medtronic. Our goal, of course, as Ray says all the time, is to be the market leader. We're doing everything we can now to act like the market leader. I'm gonna pile on to that. I mean, this year we had 1.4 million individuals go to our websites to learn about these therapies. Of those individuals, 107,000 of them filled out a symptom survey to tell us who they are, where they're located, and so forth, raising their hand basically to say, "I'd like to get a consult with a physician." We're overwhelmed with people that are, you know, hearing about this for the first time. Here's the additional interesting fact. 60% of the individuals that are filling out these symptom surveys are treatment naive. They've never even been to a doctor. I mean, if that doesn't underscore the fact that we've got this huge greenfield opportunity ahead of us, I don't know what else could. That's great. I guess what is the average age of an S&M patient, and why would they opt for a short-term solution like BOTOX rather than a long-lasting solution? That's a great question 'cause I'm still scratching my head why... Our average patient is a woman who's 57 years old. This is a chronic condition that's not going away. Why would you, why would you accept a BOTOX injection in your bladder that lasts four to six months and has a 20% chance of creating a urinary tract infection, which is a nasty problem to have, exasperates your symptoms, and of course is dangerous? It's the mindset of the providers. We've got to work on them to say, "Look, sacral neuromodulation is not your grandfather's product, right? These are new modern technology products that are easy to use, that provide great symptom relief, and so on and so forth. We've got a huge opportunity now. I mean, 150,000 people got BOTOX injections, in 2022, and the thing about it is 75% of these patients, they drop out after the second set of injections. The physicians are not doing a service to these patients. We've got work to do to be able to you know, persuade them that if you work with Axonics and you work with our technology, your patients are gonna do really well, and so on and so forth. It's, we still to this day, it just seems very illogical to us, but we're working on changing the perceptions out there. Great. The strong results you have posted in S&M throughout 2022 suggests F15 was a major driver of growth acceleration, and Axonics launched F15 primary in April of 2022, and we're now in January of 2023. Is F15 still bringing new accounts your way, or will most of the growth in 2023 come from utilization increases? I think it's as Dan mentioned. I think really it's same store sales that we're focused on. We see increases in utilization. It's a really. I hate to say it this way, but because it's confidence game, right? I mean, if the physicians have confidence in the company and the technology and how it's gonna work for their patients, they're more willing to talk about it. We all know as consumers of healthcare, when we're sitting across the table from a physician, and they're talking about treatment options, you can read it. You can tell. Are they confident about this? Are they prescribing it, or are they just recommending it or saying you should consider, right? so really its -- we gotta get the providers to be more confident in the therapy as well, and then they'll offer it more to the patient. I think it's really as simple as that. And we've done a lot of things to provide tools so that, you know, patients can get educated while they're in the physician's office, right? Storybooks, counter cards, you know, all kinds of materials you can read and so on and so forth. It's not one thing, it's a combination of many activities Right. The thing I would add is prior to Axonics bringing our rechargeable product to market, the only option that physicians had up to that point with sacral neuromodulation was a 14 cc device that, as Ray mentioned, only lasts 2-5 years and was not MRI compatible. When we launched Axonics F15 in early 2022, I mean, here you're talking about a product that's qualified to last 15-22 years in the body. You don't ever have to recharge it. It's only 10 cc's, and it's 1.5T and 3T MRI compatible with the best labeling in the industry. You can just imagine, physicians were used to a recharge-free product. We, quite honestly, simply gave them what they wanted, which was a much better version of a recharge-free product, which is easy for the physicians to be confident with, and it's very easy for a patient to say yes to that product. People want longevity and efficacy. I mean, ultimately, right? If any of us were in the same you know, situation, it's logical. That's what you want. Now we're producing products that literally, given the average age of our patients, they're gonna last for the rest of their life, which is pretty cool, you know, proposition for people to buy into. Great. Questions in audience? Do we have any questions from the audience? Okay. Sure. I'm sorry. I realize we have a mixed group and so it's. We sell primarily to urologists and urogynecologists. Some GYNs as well. Those are the main physician groups that we sell to. We'll take the question over there. That was my question. Okay, great. Yep. Anybody else with a mic? All right. I guess maybe another question. He had a question. He said, "Is your stock on sale this week?" Yes, it is. Yes, it is. How concerned are you about better products? You know, we're not because they've already done all the things that they really could have done, I think, in the short run. You could imagine they were a little bit taken back by the initial success that we had in the marketplace. They did a number of things. They, number one, they refreshed their product. They did testing to get MRI compatibility to be able to say, you don't have to pull their devices out of the body. They did that back in 2020, mid-2020. They came out with a refreshed, a non-rechargeable device that will last eight to 10 years. We've trumped them in the product portfolio all along the way. They tried to come out with a rechargeable product, which in fairness, has failed in the marketplace. We think we're leaps and bounds ahead of them from a technology standpoint and really not concerned. Now, having said that, we have a lot of respect for Medtronic. They're a big company. They've been embedded in this market for a long time. It takes a while to displace a big company like that. It's not from a technology standpoint. Clearly, our products are superior, and even the most casual observer can conclude that very quickly. Thank you. Yeah, sure. Thanks for the question. Any more questions? I got a mic here. Hang on a moment. I can't see anything. I can see you very well. I see you. Thank you. What do you think is the patient's preference? Do they prefer the F 15 or R 15 or so? Depends. You know, it's difficult to. Every individual is different. They may have different reasons. I would say that it tends to skew if the older the patient, the less they seem to get offered the rechargeable device, right? If you're 70-plus years old, you're probably gonna get the non-rechargeable device. If you're younger, you know, the concept of putting a belt around your body and recharging something for an hour... Right now, our rechargeable device is 1 hour every month. I probably should have said that from the beginning. The product that is currently expected to get FDA approval, in the next weeks has a recharging interval of 1 hour every 6-10 months. These are not burdensome. This is not like a device that you have to charge every day, right? This is a, you know, really long rechargeable periods. The rechargeable device is smaller, too, right? It's only five cc's in volume. If you're, you know, concerned about body habitus or seeing the product at all, then obviously you'd go for the smaller device. Not to say the other one's very large at all, but anyway. In the end, we're agnostic as a company. We're agnostic, and we really believe that the physician should also be agnostic and kinda, you know, get a sense about what the patient thinks and then just move in that direction. As it turns out, about 2/3 of our business is the long-lived, non-rechargeable product right now. Any other questions? Okay. You got one? Maybe a question about your DTC strategy. I know you guys added national television to your DTC strategy. What are the key learnings from the campaign thus far in terms of patient demographics? I think that in terms of the patients, I mean, it's primarily women that are responding, which is not a surprise to us, of course. The average age is in that 50-65 range. That seems to be, you know, most of them. The biggest surprise for us has been the fact that 60% of the patients filling out symptom surveys being the most motivated people to take the time to tell us about what their problem is in the fact that they have not seen a physician and that they're treatment naive. That's been the, you know, what we have, you know, gleaned from, you know, doing national television advertising and Facebook advertising now for 9 months. You know, what we need to work on as operators of the business is, you know, we got 10,000 people every month filling out a survey, raising their hand, and you can imagine that's a lot of people to call and try to get them scheduled, you know, with a provider in their area. You know, as guys focused on execution, that's really what we're focused on. Getting people to be interested and to respond seems to be the easy part. You know. It's only a 30-second spot that we're running, so it's not like, you know, we're providing that much information. It's clear that this is helpful, and I will tell you we get a lot of credit from our customers because Axonics acts like the market leader, even though statistically we may not be yet. That goes a long way with these physicians and institutions. It's about awareness, which is we talk about the 78 million women and the two paths for overactive bladder or stress urinary incontinence. The reality is when you go out into the world and you talk to patients, and then you see what happens in the practices, you know, the biggest obstacle is awareness, which is people are just not aware these therapies exist. Go back three years. If you were a patient, you went to a practice, you saw a physician with these conditions, if you didn't talk to the one physician that implanted sacral neuromodulation, you'd get prescribed a drug, you'd go home. We know that, you know, there are roughly three million new patients on overactive bladder drugs annually. 75%-80% of those patients drop out in the first year because the drugs have low efficacy, and they all have side effects. Despite that fact, they're just lost in the care pathway. If you didn't see the physician that did the procedures, you were never going to hear about sacral neuromodulation. We're working to change that, and we're changing that through innovation and by doing basic blocking and tackling marketing. As Ray mentioned, the DTC campaign has been really helpful because it's driving awareness from people to then go into the practices and talk to these physicians. It's also showing the physicians and their nursing staff that we're dedicated to this patient population, we're dedicated to their practices, we're very focused on this, and we take it seriously. We are acting like the market leader, even if we have 1/3 of the market today. You know, it's interesting. One of the things that we do that's the most productive is that we work with these physicians, we get a mailing out to their existing patient base, right? Anybody who's been differentially diagnosed, as an example, with overactive bladder, you know, we wanna pull those names, not us, but the practice, pull the names out of their electronic database or their paper files and just send them a letter. We just send a simple letter, talk about very simply there's new technology available to treat your condition, give them a have a symptom survey in there and a pre-addressed envelope, so they can respond. We're seeing amazing responses. You know, a typical physician practice might send out, say, 500 of these letters. We're seeing 5%-10%, so that's 25-50 patients raising their hand. These are already patients in the practice saying, "Yeah, I'm interested in this." These patients are coming in, and we're seeing, you know, maybe as much as half of them getting procedures done. That just underscores Dan's point that patients were getting prescribed drugs. They're leaving the office, and unfortunately, there's no follow-up, and the assumption is, well, if the patient didn't come back complaining, they must be cured, right? We know that's not the case. When we get these mailings out and all of a sudden the physician sees their own patients flooding back into their practice, that really underscores the fact that, you know, this has really been an undertreated, underserved population. That... You know, we talk about DTC, but actually, it's the direct-to-patient mailing that provides the greatest return for us of all the different activities that we're doing. You can see that, you know, we've got a lot of work to do in different areas, but it's going well for the company. We have great momentum in the business, and we're excited about the future prospects. I think that there's such an undertreated population here. We think we've got a huge greenfield opportunity ahead of us, and we're focused as we have been since day one when Dan and I started this company. It's all about execution. We're focused on all the minutiae that is necessary to be able to not only, you know, build quality products that last a long time, you know, but do things with high quality in terms of everything from manufacturing and so on and so forth. We're not leaving these patients alone to fend for themselves, right? We've got the team out there to make sure people are doing well. That's our commitment to our, you know, provider customers. Great. I think we have time for maybe a couple more questions, if there are any. All right. It's cocktail hour. May, maybe one other question before we part. Just maybe what are you most excited about for this upcoming year? I don't know. I mean, I think what we're all excited about. You know, there's a core team, and Ray mentioned it earlier. You know, the reason that we were able to take, you know, some licensed patents, you know, from the Alfred Mann Foundation and turn it into a world-class innovative product is because there's this core team of engineers and ops engineers that have worked together for over 25 years. They were together with Ray at Cardiac Science. They were with us at Vessix Vascular. They've been with us at Axonics. To be able to take a company from an idea and a vision to treat this patient population that suffers from this horribly debilitating chronic condition, which is incontinence, and to see treating tens of thousands of patients and to see the receptivity from the physicians, the nursing staff, and the patients themselves, and how it gives them back their lives. They can go back to work. They can take vacations with family. They basically get to go back into the world without having to plan every single step of the day around where they're gonna have to rush to the bathroom and change into a different pair of black clothes. What's most exciting, I think, for the entire team is this mission-driven focus on we know we're doing something that's critically important. We're executing, and we're firing on all cylinders. The best is yet to come because there are so many millions of patients yet to be treated. I think, you know, we're looking at this as what's it look like over the next five to seven years, not the next, you know, call it four quarters. It's just a tremendous opportunity, and I think we all feel very, very lucky that we've been together and that we've been able to execute this plan the way that we have, and that it's just gone so well. I would say that, you know, look, we just wrapped up our global sales meeting. We had all the salespeople and everybody in the company together to talk about 2023. Our objective is to treat 100,000 patients in 2023. That's our objective. We can meet that. We've got something to celebrate, you know, come the end of this year. Thank you for the opportunity. Appreciate your questions. Thanks for everybody for your interest in Axonics. We hope to see you as shareholders. Thank you. Thank you. Thank you.